Other News To Note
Monday, July 9, 2012
R-Pharm, of Moscow, recently inked a deal with Whitehouse Station, N.J.-based Merck & Co. Inc. for rights to an investigational hepatitis C virus (HCV) once-daily protease inhibitor, narlaprevir. Under the terms, R-Pharm gains the right to develop and commercialize narlaprevir in Russia and the Commonwealth of Independent States in exchange for an undisclosed up-front payment and royalties.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.